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AbstrACt
Introduction Opioid prescribing has increased 15-fold in 
Australia in the past two decades, alongside increases in a 
range of opioid-related harms such as opioid dependence 
and overdose. However, despite concerns about increasing 
opioid use, extramedical use and harms, there is a lack of 
population-level evidence about the drivers of long-term 
prescribed opioid use, dependence, overdose and other 
harms.
Methods and analysis We will form a cohort of all 
adult residents in New South Wales (NSW), Australia, 
who initiated prescribed opioids from 2002 using 
Pharmaceutical Benefits Scheme dispensing records. This 
cohort will be linked to a wide range of other datasets 
containing information on sociodemographic and clinical 
characteristics, health service use and adverse outcomes 
(eg, opioid dependence and non-fatal and fatal overdose). 
Analyses will initially examine patterns and predictors 
of prescribed opioid use and then apply regression and 
survival analysis to quantify the risks and risk factors of 
adverse outcomes associated with prescribed opioid use.
Ethics and dissemination This study has received full 
ethical approval from the Australian Institute of Health 
and Welfare Ethics Committee, the NSW Population and 
Health Services Research Committee and the ACT Health 
Human Research Ethics Committee. This will be the largest 
postmarketing surveillance study of prescribed opioids 
undertaken in Australia, linking exposure and outcomes 
and examining risk factors for adverse outcomes of 
prescribed opioids. As such, this work has important 
translational promise, with direct relevance to regulatory 
authorities and agencies worldwide. Project findings 
will be disseminated at scientific conferences and in 
peer-reviewed journals. We will also conduct targeted 
dissemination with policy makers, professional bodies 
and peak bodies in the pain, medicine and addiction fields 
through stakeholder workshops and advisory groups. 
Results will be reported in accordance with the REporting 
of studies Conducted using Observational Routinely 
collected Data (RECORD) Statement.
IntroduCtIon 
Australia has seen dramatic shifts in the 
rate of opioid prescribing in the last two 
decades, including changes in the types of 
opioids prescribed. Almost 15 million opioid 
prescriptions were dispensed in Australia 
in 20151 and prescribing increased 15-fold 
between 1992 and 2012.2 Originally regis-
tered to manage cancer and acute pain, since 
1999, opioids have been approved to treat 
an increasing number of chronic non-cancer 
pain (CNCP) conditions,3 despite a lack of 
evidence of long-term effectiveness.4–6 
There has also been a shift in the type of 
opioids prescribed. In 1990, 90% of opioid 
dispensings were for so-called weak opioids 
and 96% were short-acting opioids.3 By 2011, 
40% of dispensings were for strong opioid 
and 50% for long-acting opioids.3 In parallel 
to escalating use, there is increasing extra-
medical opioid use, injection, opioid-related 
hospitalisation, opioid dependence and 
overdose.7–10
Oxycodone has received considerable 
attention due to associated harms.11–13 Its 
prescription has played a significant part 
in the US opioid epidemic.14 Australian 
evidence suggests patients at higher risk of 
adverse opioid outcomes may have a higher 
likelihood of being prescribed oxycodone15; 
oxycodone is by far the most commonly 
strengths and limitations of this study
 ► This will be the largest postmarketing surveillance 
study of prescribed opioids undertaken in Australia, 
linking exposure and outcomes and examining risk 
factors for adverse outcomes of prescribed opioids.
 ► The size of the cohort permits in-depth analyses 
and comparisons of outcomes for different patient 
groups, types of opioids prescribed and across dif-
ferent time periods.
 ► Estimating opioid exposure in pharmaceutical 
claims data is a complex undertaking and will be 
challenging.
 ► Self-reported health and outcome measures are not 
available from linked administrative data sources 
and will therefore be assessed using validated tools 
and proxy measures.
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misused prescription opioid.16 17 This is concerning given 
oxycodone utilisation increased 12-fold in Australia since 
2000, now accounting for 34% of all pharmaceutical 
opioid use.3 18
Oxycodone is not the only concern. The prescribed 
opioid market is highly dynamic. The Pharmaceutical 
Benefits Advisory Committee (PBAC)—Australia’s 
expert advisory group that makes recommendations 
to the Federal government about medicine listings on 
the national Pharmaceutical Benefits Scheme (PBS)—
receives three to six applications for opioid listings annu-
ally. Between 2000 and 2016, the PBAC has approved 37 
new opioids, formulations, strengths and indications, 
including formulations intended to deter extramedical 
use and diversion and reduce harms. Yet, there is little 
evidence to inform possible PBAC decisions such as 
limiting the number of subsidised opioids, dose ranges, 
duration of therapy and formulations. There are chal-
lenges for regulatory agencies and third-party payers in 
this area with regards to balancing treatment access for 
pain and the risks of inappropriate prescribing.
Pharmaceutical opioid use is increasing rapidly
CNCP, cancer pain and injuries are major causes of disease 
burden.19 Cancer accounts for 17% of the total burden of 
disease (measured by both disability and death), CNCP 
for 13% of burden and injuries for 8%.19 The burden 
associated with these conditions, especially CNCP, has 
increased in many high-income countries with ageing 
populations.19 As the Australian population ages, these 
burdens will continue to increase. In direct line with this 
increasing health burden, as documented above, utilisa-
tion of prescription and non-prescription opioids has also 
dramatically increased.
There are many potential risks of this escalating trend 
in opioid utilisation. The US example is sobering: it is 
experiencing an unprecedented epidemic of opioid use 
and dependence, with substantial increases in opioid 
deaths,20 initiation of heroin use in people prescribed 
opioids21 and enormous strain on the health system. 
The problems observed with opioid use in the USA have 
been driven substantially by widespread prescribing of 
long-acting and strong opioids, such as oxycodone and 
fentanyl.22 23 In 1995, the US Food and Drug Administra-
tion (FDA) approved the use of controlled-release oxyco-
done (CRO) for ‘initial treatment for moderate to severe 
non-cancer pain’. It was heavily marketed for use in 
CNCP, with unsubstantiated claims that it minimised risks 
of extramedical use and dependence.14 Ten years later, 
an opioid epidemic was well underway.11 13 Fatal opioid 
overdoses now outnumber road accident deaths in the 
USA,24 opioids are among the top five causes of hospi-
talisation25 and decreases in life expectancy among white 
non-Hispanic people in the USA have been attributed to 
escalating fatal opioid overdoses.26
In 2016, the US government provided an additional 
US$1.1 billion in funding to expand opioid dependence 
treatment, and more conservative guidelines for opioid 
prescribing from the US Centers for Disease Control 
were introduced.27 Other strategies that have been imple-
mented include the development of so-called abuse-deter-
rent formulations of opioids intended to be less attractive 
for diversion or tampering.28 However, questions remain 
as to the potential for these formulations to achieve 
substantial decreases in extramedical use, diversion and 
harms.29
Despite the differences in Australia’s healthcare system, 
there is strong evidence that we are heading in the same 
direction. In Australia, long-acting formulations are 
recommended as first-line opioid treatments of CNCP,30 
which is estimated to affect one in five Australians.31 
There is considerable concern about the appropriate-
ness of long-term opioid prescribing for CNCP,32 and 
we are seeing increases in opioid-related hospital admis-
sions, dependence and overdose7–10 33; pharmaceutical 
opioids now cause over 70% of opioid overdose deaths in 
Australia.33 It is therefore imperative to quantify the risks 
associated with different opioids and identify those most 
at risk of harm, in order to prevent and reduce further 
harms.
We have a limited understanding of the patterns of utilisation 
and extramedical use of different opioids in Australia
Work to date in Australia and the USA has lacked the 
capacity to shed light on the magnitude of risks faced by 
people prescribed different opioids and individual risks 
for adverse outcomes. For example, through analysis of 
sales data, we found greater strong opioid utilisation in 
socioeconomically disadvantaged areas,18 but these data 
do not inform us about individual-level utilisation, nor 
permit any understanding of outcomes of this higher 
utilisation. We have documented increases in pharma-
ceutical overdose deaths,8–10 with oxycodone featuring 
prominently and fentanyl increasing,8 but this tells us very 
little about risk factors for such deaths, the trajectory of 
opioid utilisation leading to death and the risks for other 
adverse outcomes of opioids (including other causes of 
death).
Australian prescribing guidelines recommend oxyco-
done as a first-line opioid for use in CNCP and also in 
acute pain when simple analgesics are not effective.30 Our 
previous research has shown 73% of people initiating 
strong opioids in Australia are now dispensed oxyco-
done,34 with oxycodone much more likely to be used 
without prior trial of less potent or non-opioid analge-
sics.34 Furthermore, people with acute and CNCP pain are 
more likely to be given oxycodone than those with cancer 
pain.34 Fentanyl and buprenorphine are also commonly 
used in CNCP.15 35 36 Without linkage to outcome data, we 
cannot determine what proportion of this prescribing is 
appropriate nor understand the relationship of prescrip-
tion to harms, as dispensing data alone does not provide 
information about clinical characteristics of the patients 
nor indicate risk of adverse outcomes.
In a cohort of people with CNCP taking opioids 
(n=1500),15 we found that people taking oxycodone (vs 
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other opioids) had higher risks of opioid dependence, 
aberrant opioid use and other opioid harm.15 We also 
found those prescribed oxycodone were more likely to 
be: taking higher doses, younger and have mental health 
issues and substance use disorders.15 It is unclear whether 
this cohort is representative of all patients with CNCP, 
and cross-sectional analysis precludes any capacity to infer 
causality. The risks faced by patients initially prescribed 
opioids for other indications remains unknown.
In summary, each of these findings shed light on 
concerning features of Australian opioid prescribing that 
underpin the rationale for this study. Their limitations 
mean that more information is needed to understand 
who faces these risks and whether there are different risks 
for different opioids.
We need to identify patients at highest risk for adverse opioid 
outcomes
A range of patient characteristics has been associated 
with adverse outcomes, for example, overdose mortality, 
including younger age, male gender, lower socioeco-
nomic status and mental health comorbidity.37–40 The 
term ‘adverse selection’ has been used to describe this 
apparent contradiction, whereby the likelihood of a 
patient receiving opioid therapy increases as the number 
of risk factors for adverse outcomes increases.40 However, 
much of this work is derived from cross-sectional or 
retrospective analyses of highly selected patient samples 
(typically those with CNCP), with limited capacity to 
understand risks of less selected patients using opioids for 
other reasons (eg, cancer and acute pain).
We need to move from signal detection of harms to 
quantification of harm
Since 1961, the WHO Programme for International Drug 
Monitoring has collated reports of adverse drug reactions 
(ADRs).41 There is increasing recognition that relatively 
passive systems of ADR detection fall far short of what 
is needed to understand the magnitude of medicines’ 
risks.42 Contemporary postmarketing surveillance (PMS) 
quantifies the outcomes associated with specific medicine 
exposures.42 Active PMS is increasingly required: the US 
FDA has dramatically increased its requirements, judging 
earlier requirements inadequate.43
The International Association for the Study of Pain 
(IASP) Position Statement on Opioids states ‘IASP also 
strongly advocates for continued research to identify ways 
to minimise opioid risk…’ showing the importance of 
robust risk assessment frameworks.44 We have a unique 
opportunity to undertake such work, quantifying the 
extent and nature of opioid risk in Australia. We will apply 
a consistent framework of risk assessment to the entire 
range of prescribed opioids, with long-registered opioids 
assessed alongside more recently registered opioids. The 
contrast with older opioids (eg, morphine) is important 
because few requirements to document risks existed at 
the time of approval. We have a particular focus on strong 
and long-acting opioids.
AIMs
We will form a population-based cohort of adult residents 
in New South Wales (NSW), Australia, who initiated 
prescribed opioids from 2002, with linkage to a range of 
datasets providing rich information on sociodemographic 
and clinical characteristics, health service use and adverse 
outcomes. Our study will meet three aims:
1. Identify patterns of utilisation of different opioids, in-
cluding indications of non-adherent or aberrant utili-
sation and establish predictors of different patterns of 
opioid use.
2. Quantify the risks of adverse outcomes of prescribed 
opioids and establish predictors of such outcomes, in-
cluding indicators for prescription, comorbid mental 
health and physical problems, sociodemographic char-
acteristics, patterns of other health service use and oth-
er medicines use.
3. Examine the population-level impact of changes in 
regulation and subsidy of opioids on patterns of utilisa-
tion and risks of adverse outcomes.
MEthods And AnAlysIs
setting
Australia has a publicly funded universal healthcare system 
entitling all Australian citizens and permanent residents 
to a range of subsidised health services. This includes 
free treatment in public hospitals (funded jointly by 
Commonwealth and State/Territory governments), subsi-
dised outpatient services including consultations with 
medical and selected healthcare professionals (funded 
by the Commonwealth’s Medicare Benefits Scheme) 
and medicines prescribed in the community and private 
hospitals (funded by the PBS).45 Medicines prescribed 
to public hospital inpatients are covered primarily by 
hospital budgets.
Cohort definition
The cohort will comprise all adult NSW residents who 
initiated a new opioid dispensing episode from 2002 to 
most recently available using PBS dispensing records. A 
new episode will be defined as the first time we observe 
a PBS record for a prescribed opioid after a period of at 
least 90 days with no opioid dispensing records. PBS-listed 
opioid analgesics include: oxycodone, fentanyl, codeine, 
dextropropoxyphene, hydromorphone, morphine, peth-
idine, tapentadol, tramadol, buprenorphine and meth-
adone. The complete list of all Anatomical Therapeutic 
Chemical46 and PBS item codes that will be used to 
extract the cohort is included in online supplementary 
appendix A. People initiating methadone or buprenor-
phine for opioid dependence are not included. Private 
prescriptions (ie, those in which the patient pays the 
full cost themselves, with no government subsidy) are 
not included, but these form a very small proportion of 
overall opioid prescriptions.47
This study is informed by our earlier work examining 
patterns of opioid use and access.34 48–50 We have recently 
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validated the PBS dataset as a data source for examining 
population-level opioid utilisation across Australia.47 We 
have also completed a number of sensitivity analyses to 
examine the effect of varying the opioid-free window used 
to identify people initiating opioids,34 50 demonstrating 
this is a feasible and acceptable method of defining an 
incident cohort of persons initiating opioids.
datasets and linkage
We will link to 10 Commonwealth and NSW/Australian 
Capital Territory (ACT) collections (table 1). ACT data 
collections are included to increase capture of service 
use by our cohort that may occur in that jurisdiction 
(ACT is situated within NSW).51 The Australian Institute 
of Health and Welfare (AIHW) will undertake the data 
linkage in conjunction with the Centre for Health Record 
Linkage (CHeReL), who will undertake the linkage of the 
NSW/ACT collections once the AIHW has established 
the cohort. AIHW and the CHeReL have track records 
of quality record linkage and privacy-preserving proce-
dures. Files containing identifying information will be 
linked using probabilistic record linkage techniques. 
Coded (non-personally identifiable) matched files will 
be forwarded to the Secure Unified Research Environ-
ment (SURE) facility for access by our team. We will use a 
Table 1 Description of datasets to be linked*
Dataset name and year of 
first record Description of dataset Purpose of dataset Key variables of interest
Pharmaceutical Benefits 
Scheme (PBS, 2002)
Records for all PBS-listed 
medicines for which the 
Commonwealth pays a 
subsidy (2002–2012). After 
2012, all PBS dispensings are 
included.
To identify the cohort and the 
types of opioids and other 
medicines prescribed.
PBS-item number, date of 
prescribing and dispensing, 
patient copayment, cost to 
government and provider 
location.
Medicare Benefits Scheme 
(MBS, 2002)
Claims for all medical and 
hospital services subsidised 
by the Commonwealth 
including doctor visits, 
pathology tests and imaging.
To identify the use of medical 
and hospital services.
MBS-item number, date of 
service, schedule fee, provider 
charge, benefit paid, patient 
copayment and provider 
location.
Australian Cancer Database 
(ACD, 1982)
All notifications of primary 
malignant neoplasms.
To identify individuals treated 
with opioids for cancer pain.
Date of diagnosis, topography 
and morphology codes and 
degree of spread.
National Death Index (NDI, 
2002)
Death registrations and 
causes of death.
To calculate mortality rates 
for the cohort and censor 
individuals.
Date of death, underlying and 
contributing causes of death.
NSW Admitted Patient Data 
Collection (NSW APDC, 2001); 
ACT Admitted Patient Care 
(ACT APC, 2004)
Census of all inpatient 
episodes in all NSW/ACT 
public and private hospitals, 
public multi-purpose services 
and private day procedure 
centres.
To identify harms and risks 
associated with prescribed 
opioids.
Dates of admission, separation 
and procedures, diagnostic 
and procedure codes, 
admission costs, separation 
mode, hospital type and  
hospital location.
NSW Emergency Department 
Data Collection (NSW EDDC, 
2005); ACT Emergency 
Department Data Collection 
(ACT EDDC, 2005)
All visits to participating 
emergency departments in 
NSW/ACT.
To identify harms and risks 
associated with prescribed 
opioids.
Dates of presentation and 
separation, referral source, 
arrival mode, visit type, triage, 
diagnosis and separation 
mode.
Pharmaceutical Drugs of 
Addiction System (PHDAS, 
1985) Changed to Electronic 
Recording and Reporting of 
Controlled Drugs (ERRCD) in 
September 2016.
Opioid substitution therapy 
(methadone/buprenorphine) 
treatment episodes in NSW.
To identify individuals with a 
history of opioid dependence 
and who subsequently are 
prescribed opioids. We will 
also use this as an outcome, 
examining risk of treatment for 
iatrogenic opioid dependence.
Treatment entry and exit 
dates and type of medicine 
authorised.
Mental Health Ambulatory 
Collection (MH-AMB, 2001)
Records on the assessment, 
treatment, rehabilitation or 
care of non-admitted mental 
health patients in NSW.
To identify individuals with 
mental health disorders and 
their treatment patterns.
Date of service, mental health 
diagnoses and services 
provided.
*Data will be provided from the year indicated. Most collections hold patient demographics including age, sex, location of residence mapped 
to the socioeconomic80 and remoteness classifications.81
ACT, Australian Capital Territory; NSW, New South Wales
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range of pharmacoepidemiological techniques, measure-
ment methods and analyses, summarised across the three 
overall aims below.
Patient and public involvement
Patients were not involved in the design of the study. As 
described in our dissemination activities, results from this 
study will be disseminated through one-page summaries 
distributed to pain clinics, consumer groups and peak 
bodies. Key findings will also be disseminated via media 
releases to encourage discussion of findings in a wide 
variety of news and information outlets.
Analytical plan
Aim 1: identify patterns of opioid utilisation and establish 
predictors of those trajectories
Defining opioid exposure
The 11 PBS-listed opioid analgesics vary in their strength, 
potency, formulation, duration of action and route of 
administration. PBS records do not contain information 
on prescribed daily dose or the number of days of supply. 
Therefore, we will estimate the standard coverage days 
(SCDs)—the median time to resupply of each opioid. We 
will define a break in opioid treatment as a gap of three 
SCDs from the date of the last dispensing, consistent with 
our definition of new treatment. When a treatment break 
is observed, we will calculate duration of a treatment 
episode as time from the first prescription to the last 
prescription plus one SCD. To assess duration of opioid 
therapy, we will use Kaplan-Meier methods. Concomitant 
opioid use will be defined as any overlap in SCDs for the 
same or different opioids.
We will estimate the average daily opioid dose per 
prescription as the quantity of opioids dispensed multi-
plied by their strength (in mg) and divided by the SCD for 
that opioid. We will calculate total daily opioid exposure 
using oral morphine equivalent (OME) milligrams using 
conversion factors that have been previously developed 
and synthesised by our group.52 This allows for estimates 
of total opioid exposure to be presented in a common 
metric for each individual on each day.
Many people will be using multiple strengths of 
an opioid, or more than one opioid on a given day, 
particularly for more severe cancer pain and CNCP, 
although the clinical justification for multiple opioids is 
absent.32 Our definitions of opioid exposure will account 
for the range of opioids available and their likely concom-
itant use. We will also move beyond simplistic exposure 
measures (yes/no) to models that more closely reflect 
real-world medicine use, recognising that medicines 
exposure changes over time. Analysing opioid exposure 
as a time-dependent variable provides unbiased risk esti-
mates of drug-outcome associations. Sensitivity analyses 
will determine the impact of varying these definitions.
Patterns of opioid use 
Patterns of opioid use will be operationalised in several 
different ways: 
a.  Median duration of opioid treatment: defined as the time 
from the first opioid dispensing record to the last dis-
pensing record plus 30 days. These estimates can also 
detail different courses of opioid therapy by account-
ing for breaks in treatment of more than 60 days. 
b.  Dose escalation: we will estimate the average daily dose 
of each opioid prescription dispensed using daily OME 
mg52; this gives us the capacity to track opioid utilisa-
tion across a patient’s use of different opioids or opioid 
formulations within a given treatment episode. We will 
calculate the changes in average daily doses by pre-
scription and report the number of patients in whom 
doses are increasing, and by what level, over time. 
c.  Concomitant use of opioids and other medicines: we will in-
vestigate the concomitant use of multiple opioids, in 
addition to the use of opioids with other prescribed 
medicines, such as benzodiazepines, antidepressants 
and antipsychotics. Concomitant use will generally 
be defined as the observation of at least two dispens-
ing records from different medicines within a specific 
timeframe of each other. Rules will vary according to 
the medicines of interest. Furthermore, we will identi-
fy individuals at risk of potentially harmful drug–drug 
interactions deemed to be clinically relevant in the lit-
erature and common drug information resources (eg, 
opioids and benzodiazepines).53–55 These will be exam-
ined using a previously published approach, 56 overall, 
Table 2 Operationalisation of indications
Indication Examples of source and definitions that may be operationalised
Cancer Defined via Cancer registry: solid cancers classified via ICD-10 Haematopoietic neoplasms82; kaposi 
sarcomas classified according to ICD for Oncology third edition.83
Back/neck pain Defined via MBS/PBS/EDDC/APC/APDC. APC/APDC: ICD-10 codes M54.82
Rheumatoid arthritis Defined via MBS/PBS/EDDC/APC/APDC. APC/APDC: ICD-10 codes M05 and M06.82
Other pain conditions Defined via MBS/PBS/EDDC/APC/APDC. APC/APDC: ICD-10 codes will be grouped into categories 
in line with previous work.34
Traffic/other injuries Defined via EDDC/APC/APDC. APDC: ICD-10 codes V00-V89.82
APC, Australian Capital Territory Admitted Patient Care; APDC, New South Wales Admitted Patients Data Collection; EDDC, Australian Capital 
Territory and New South Wales Emergency Department Data Collections; ICD-10, International Statistical Classification of Diseases and 
Related Health Problems, 10th Revision; MBS, Medical Benefits Scheme; PBS, Pharmaceutical Benefits Scheme.
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and for specific population subgroups such as older 
adults.
Extramedical opioid use 
Extramedical opioid use will be defined and operation-
alised from existing literature.57 We will report rates of: 
a. Excess dosing: defined as average daily dosing outside 
guideline recommendations.58–60
b. Concomitant opioid use: as described above.59 61
c. Doctor shopping: prescriptions by multiple doctors at 
medical different practices, dispensed within a specific 
timeframe.62–71
d. Accelerated prescription refill: repeated dispensing of opi-
oids earlier than the time when the dispensing epi-
sode is expected to be complete.59 60 72–75 This will be 
based on the medication possession ratio and refill 
compliance.
Defining patient groups
Table 2 lists examples of patient groups (this is not exhaus-
tive). As per our outcomes of interest, our definitions will 
be based on existing expert recommendations,34 35 consul-
tation with data custodians and with clinical experts from 
our team of investigators and externally.
Key covariates
We will define a broad range of important clinical and demo-
graphic covariates across the linked datasets (see examples 
in table 3), ensuring we cover domains identified by pain 
experts as key in analyses of opioid outcomes.36 These will 
include definitions of key patient groups as defined in 
table 2 (eg, cancer). These will be initially defined at the 
time of the index opioid prescription. For the survival anal-
yses of risk factors for adverse opioid outcomes, these vari-
ables will be considered as time dynamic variables.
Aim 2: quantify risks of adverse opioid-related outcomes and 
establish predictors of outcomes
provides examples of our approach to identify indicators 
of opioid-related adverse outcomes. We will use definitions 
of adverse outcomes consistent with expert recommenda-
tions.34 35 In cases where none exist, we will develop defi-
nitions in consultation with data custodians and clinical 
experts from our team of investigators and externally.
We will calculate the event rate (per 1000 days of use) 
for each adverse outcome examined (see examples in 
table 4) for each of the opioids by age-group and sex, 
with CIs derived from a Poisson or negative binomial 
distribution as appropriate. We will use survival analytic 
Table 4 Operationalisation of example outcomes
Example outcomes Examples of source and definitions that may be operationalised
Opioid use disorders APC/APDC: ICD-10 opioid use disorder (F11 codes)82; EDDC; and PHDAS.
Opioid dependence treatment PHDAS: entry into opioid substitution therapy.
Falls APC/APDC: ICD-10 slipping, tripping, stumbling and falls (W00-W19).82
Non-fatal opioid overdose APC/APDC: ICD-10 opioid poisoning (X42, X44 with T codes).82
Accidental opioid-induced death NDI: ICD-10 codes for opioid use disorders or poisoning (F11; F19 with F11; F19, X42, X44 
with T codes for opioids).82
APC, Australian Capital Territory Admitted Patient Care; APDC, New South Wales Admitted Patients Data Collection; EDDC, Australian Capital 
Territory and New South Wales Emergency Department Data Collections; ICD-10, International Statistical Classification of Diseases and 
Related Health Problems 10th Revision; MH-AMB, Mental Health Ambulatory Collection; NDI, National Deaths Index; PHDAS, Pharmaceutical 
Drugs of Addiction System.
Table 3 Operationalisation of covariates from available data sources
Covariates Source and examples of definitions that may be operationalised.
Sociodemographics PBS: age, sex, area of residence, beneficiary status (concessional, general and repatriation).
Prescription medicine use PBS: history of other medicine use, specified by drug class, for example, benzodiazepines.
Extent of comorbidity APC/APDC: application of the Charlson comorbidity index84; PBS: application of the RxRisk 
tool.85 86
Mental health history MH-AMB, MBS, PBS, EDDC and APC/APDC: treatment for mental disorders with medicines, 
mental healthcare plans, outpatient care or hospital admission.
History of suicidality EDDC and APC/APDC: prior visit for attempted suicide.
History of substance use 
problems
PHDAS: opioid dependence treatment; MH-AMB: treatment where substance use problems 
flagged; EDDC/APC/APDC: prior alcohol or illicit drug-related admissions.
APC, Australian Capital Territory Admitted Patient Care; APDC, New South Wales Admitted Patients Data Collection; EDDC,  Australian 
Capital Territory and New South Wales Emergency Department Data Collections; MBS, Medicare Benefits Scheme; MH-AMB, Mental Health 
Ambulatory Collection; NDI, National Deaths Index; PBS, Pharmaceutical Benefits Scheme; PHDAS, Pharmaceutical Drugs of Addiction 
System.
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methods to identify risk factors for adverse outcomes 
following initial opioid dispensing, comparing across 
opioids where relevant.
Each adverse outcome will be considered separately, 
with data censored at the earliest dataset conclusion or 
date of death (other than opioid-induced). Opioid-in-
duced death will be considered as a competing risk for 
all non-death outcomes. We will investigate the effect 
of repeat incident exposure to prescribed opioids by 
using methods that incorporate multiple observations 
per person (eg, frailty models, generalised linear mixed 
models and generalised estimating equations).
Risk factors will be incorporated into multivariable 
models based on univariate analyses and retained if they 
show evidence of an association with the outcome. Risk 
factors will be identified for the entire cohort, adjusting 
for patient disease group. We will assess heterogeneity 
between disease groups in the effect of risk factors and 
exposures descriptively, by constructing models within 
each disease group, and formally through hypothesis 
testing of interaction terms.
Since we have individuals’ linked hospital separations, 
we will account for time spent in hospital (and there-
fore time when the individual will not be using commu-
nity-based prescriptions). The same applies for entry 
into opioid substitution therapy. These adjustments are 
strengths of our study and something that no previous 
analyses of opioid utilisation have undertaken.
Aim 3: examining the impacts of opioid scheduling, regulation and 
subsidy changes
We will analyse the potential impact of changes in opioid 
scheduling or subsidy. We summarise the approach using 
oxycodone as an example. For example, a tamper-resis-
tant formulation (TRF) of CRO was PBS-subsidised on 1 
April 2014. Existing studies of this change17 76 could not 
examine impact at the individual patient level. We will use 
interrupted time-series analysis to assess the impact of the 
introduction of TRF-CRO on dispensing of oxycodone and 
other opioids and rates of discontinuation and switching 
from CRO to another strong opioid, using April 2014 as 
the point of change. To account for seasonality in PBS 
dispensings, long-term trends and autocorrelation, we will 
use an autoregressive integrated moving average (ARIMA) 
approach.77 We will create ARIMA models for discontinu-
ation, overall switching and switching from CRO to other 
opioids. Analyses will be stratified by indication for opioid 
prescribing, demographics and comorbid mental health 
and substance use problems. Tests will be adjusted for clus-
tering, as some individuals could switch more than once.
sample size and power analysis
Based on existing data on PBS dispensings, we will 
have ~2 million people initiating opioids during the 
study period, of whom over 400 000 will have initiated 
onto oxycodone. We will have ~13 million person-years of 
follow-up. Our study will be powered to detect even small 
differences in risks of adverse outcomes. For a rare (5%) 
exposure, we will have 90% power to detect an incidence 
rate ratio of 1.34 for an outcome with 2000 occurrences 
as statistically significant at 0.025 one-sided significance. 
Our ARIMA analyses will have more than 90% power to 
detect effect sizes of 1.78 For example, preliminary anal-
ysis of 80 mg CRO sales showed a mean of 13 760 pack 
sales/month before TRF-CRO’s introduction and an 
autoregressive term of 0.076.17 An effect size of 1 equates 
to a capacity to detect a drop of 962 pack sales/month.
Methodological considerations
There are several inherent limitations with each of the 
datasets. A key methodological consideration for this 
study is related to use of PBS data to define our cohort 
and assess exposure to prescribed opioids and other 
medicines. The PBS has two beneficiary types relating to 
the level of copayment for each medicine. General bene-
ficiaries pay a general copayment amount, and conces-
sional beneficiaries pay a lower concessional copayment 
amount. Until 2012, dispensings for PBS-listed medicines 
that attracted a government subsidy are captured. This 
occurs when the price of a medicine is above the PBS 
copayment threshold.30 All dispensings for concessional 
beneficiaries (approximately 25% of Australians33) are 
captured, since all PBS medicines cost more than the 
copayment threshold. From April 2012 onwards, the 
Department of Human Services also maintains dispensing 
records for under copayment medicines. Of particular 
importance to this study is the lack of under copayment 
data in the PBS records prior to 2012; this has direct rele-
vance as a number of PBS-listed opioids cost less than 
the general beneficiary copayment.45 To account for this 
issue, we will restrict some analyses to continuous cohorts 
of concessional beneficiaries so that we have complete 
ascertainment of their PBS medicines.
EthICs And dIssEMInAtIon
data storage, retention and access
To protect privacy and confidentiality, approval for the 
linkage of health data is provided under strict conditions 
for the storage, retention and use of the data. The current 
approval permits storage of the data at one site, UNSW 
Sydney, for up to 7 years following the date of publication 
of results. 
dissemination
This will be the largest PMS study of prescribed opioids 
undertaken in Australia, linking exposure and outcomes 
and examining risk factors for adverse outcomes of 
prescribed opioids. It will also demonstrate the capacity 
of analysis of routinely collected data to inform about 
risks of opioid prescribing before problems develop. 
As such, this work has important translational promise, 
with direct relevance to regulatory authorities and 
agencies worldwide. It will provide evidence against 
which clinical guidelines in pain management can be 
evaluated. A key audience for dissemination will be 
policy and regulatory stakeholders (eg, PBAC), general 
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practitioners, pain specialists and policy stakeholders 
in Australia and internationally. Project findings 
will be disseminated at scientific conferences and in 
peer-reviewed journals. We will also conduct targeted 
dissemination with policy makers, professional bodies 
and peak bodies in the pain, medicine and addiction 
fields (eg, via stakeholder workshops and advisory 
groups). As the study uses routinely collected health 
data, findings will be reported in accordance with the 
REporting of studies Conducted using Observational 
Routinely collected Data (RECORD) Statement.79
Author affiliations
1National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, New South 
Wales, Australia
2Centre for Big Data Research in Health, UNSW Sydney, Sydney, New South Wales, 
Australia
3IMPACCT, Faculty of Health, University of Technology Sydney, Sydney, New South 
Wales, Australia
4Concord Clinical School, The University of Sydney, Sydney, New South Wales, 
Australia
5School of Medicine and Public Health, Faculty of Health, The University of 
Newcastle, Newcastle, New South Wales, Australia
6Drug and Alcohol Clinical Services, Hunter New England, Newcastle, New South 
Wales, Australia
7Menzies Centre for Health Policy, Faculty of Medicine and Health, The University of 
Sydney, Sydney, New South Wales, Australia
Acknowledgements We wish to acknowledge our associate investigators for 
their contributions in developing the protocol for this study: Dr Andrea Schaffer, 
Dr Briony Larance, Dr Gabrielle Campbell, Dr Michael Coory, Professor Michael 
Farrell, Professor Milton Cohen, Professor Nicholas Buckley, Professor Paul Haber 
and Professor Rebecca Ivers.
Contributors All authors had involvement in developing the original protocol 
document upon which this manuscript was based. The study idea was conceived by 
NG, SAP, TD and LD. All authors provided input to the study design and developing 
the research questions and statistical analysis plan. NG and LD drafted the first 
iteration of the manuscript. All authors reviewed the manuscript and approved the 
final draft. 
Funding This work is supported by a National Health and Medical Research 
Council Health (NHMRC) project grant (#1138442). NG, SL and LD are supported by 
NHMRC research fellowships (#1091878, #1140938 and #1135991). The National 
Drug and Alcohol Research Centre at UNSW Sydney is supported by funding from 
the Australian Government under the Substance Misuse Prevention and Service 
Improvements Grant Fund. 
Competing interests The authors declare no direct competing interests relevant to 
this study protocol. Some of the authors have received investigator-initiated untied 
educational grants from Reckitt Benckiser/Indivior for studies of buprenorphine-
naloxone (LD and RPM), buprenorphine depot (LD and AD), naloxone (SL and LD), 
the development of an opioid-related behaviour scale (LD and RPM) and a study 
of opioid substitution therapy uptake among chronic non-cancer pain patients (LD 
and RPM). Some of the authors have also received investigator-initiated untied 
educational grants for postmarketing surveillance studies of a tamper-resistant 
opioid formulation from Mundipharma (LD) and for tapentadol from Seqirus Pty 
Ltd (LD). No company had any knowledge or involvement in this study. AW is paid 
by the Australian Commonwealth government as the chair of the Pharmaceutical 
Benefits Advisory Committee (PBAC). SAP is a member of the Drug Utilisation Sub-
Committee (DUSC) of the PBAC.
Patient consent Not required.
Ethics approval The study protocol has received full ethical approval 
from the Australian Institute of Health and Welfare (AIHW) Ethics Committee 
(EO2016/4/314), NSW Population and Health Services Research Committee 
(2017/HRE0208) and the ACT Health Human Research Ethics Committee 
(ETHLR.18.094). 
Provenance and peer review Not commissioned; peer reviewed for ethical and 
funding approval prior to submission.
open access This is an open access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non-commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited, appropriate credit is given, any changes made indicated, and the use 
is non-commercial. See: http:// creativecommons. org/ licenses/ by- nc/ 4. 0/.
rEFErEnCEs
 1. Pharmaceutical Benefits Division. Australian statistics on medicines 
2015. Canberra: Commonwealth of Australia, 2016.
 2. Blanch B, Pearson SA, Haber PS. An overview of the patterns of 
prescription opioid use, costs and related harms in Australia. Br J 
Clin Pharmacol 2014;78:1159–66.
 3. Karanges EA, Blanch B, Buckley NA, et al. Twenty-five years of 
prescription opioid use in Australia: a whole-of-population analysis 
using pharmaceutical claims. Br J Clin Pharmacol 2016;82:255–67.
 4. Beubler E, Jaksch W, Devulder J, et al. The White Paper on opioids 
and pain: a pan-European challenge: the European White Paper on 
the use of opioids in chronic pain management. J Pain Palliat Care 
Pharmacother 2006;20:79–87.
 5. Furlan AD, Sandoval JA, Mailis-Gagnon A, et al. Opioids for chronic 
noncancer pain: a meta-analysis of effectiveness and side effects. 
CMAJ 2006;174:1589–94.
 6. Manchikanti L, Ailinani H, Koyyalagunta D, et al. A systematic review 
of randomized trials of long-term opioid management for chronic 
non-cancer pain. Pain Physician 2011;14:91–121.
 7. Degenhardt L, Black E, Breen C, et al. Trends in morphine prescriptions, 
illicit morphine use and associated harms among regular injecting drug 
users in Australia. Drug Alcohol Rev 2006;25:403–12.
 8. Roxburgh A, Bruno R, Larance B, et al. Prescription of 
opioid analgesics and related harms in Australia. Med J Aust 
2011;195:280–4.
 9. Roxburgh A, Burns L, Drummer OH, et al. Trends in fentanyl 
prescriptions and fentanyl-related mortality in Australia. Drug Alcohol 
Rev 2013;32:269–75.
 10. Roxburgh A, Hall WD, Burns L, et al. Trends and characteristics of 
accidental and intentional codeine overdose deaths in Australia. Med 
J Aust 2015;203:299.
 11. Cicero TJ, Inciardi JA, Muñoz A. Trends in abuse of Oxycontin and 
other opioid analgesics in the United States: 2002-2004. J Pain 
2005;6:662–72.
 12. Katz N, Dart RC, Bailey E, et al. Tampering with prescription opioids: 
nature and extent of the problem, health consequences, and 
solutions. Am J Drug Alcohol Abuse 2011;37:205–17.
 13. Compton WM, Volkow ND. Major increases in opioid analgesic abuse 
in the United States: concerns and strategies. Drug Alcohol Depend 
2006;81:103–7.
 14. General Accounting Office. Prescription drugs: Oxycontin abuse and 
diversion and efforts to address the problem (GAO-04-110). 2003. 
http://www. gao. gov/ new. items/ d04110. pdf
 15. Campbell G, Nielsen S, Larance B, et al. Pharmaceutical opioid use 
and dependence among people living with chronic pain: associations 
observed within the Pain and Opioids in Treatment (POINT) Cohort. 
Pain Med 2015;16:1745–58.
 16. Larance B, Lintzeris N, Bruno R, et al. The characteristics of a cohort 
who tamper with prescribed and diverted opioid medications. J 
Subst Abuse Treat 2015;58:51–61.
 17. Degenhardt L, Bruno R, Ali R, et al. The introduction of a potentially 
abuse deterrent oxycodone formulation: Early findings from the 
Australian National Opioid Medications Abuse Deterrence (NOMAD) 
study. Drug Alcohol Depend 2015;151:56–67.
 18. Degenhardt L, Gisev N, Cama E, et al. The extent and correlates 
of community-based pharmaceutical opioid utilisation in Australia. 
Pharmacoepidemiol Drug Saf 2016;25:521–38.
 19. Kassebaum NJ, Arora M, Barber RM, et al. Global, regional, and 
national disability-adjusted life-years (DALYs) for 315 diseases and 
injuries and healthy life expectancy (HALE), 1990-2015: a systematic 
analysis for the Global Burden of Disease Study 2015. Lancet 
2016;388:1603–58.
 20. Jones CM, Mack KA, Paulozzi LJ, et al. Pharmaceutical overdose 
deaths, United States, 2010. JAMA 2013;309:657–9.
 21. Compton WM, Jones CM, Baldwin GT. Relationship between 
nonmedical prescription-opioid use and heroin use. N Engl J Med 
2016;374:154–63.
 22. Frank RG, Pollack HA. Addressing the fentanyl threat to public 
health. N Engl J Med 2017;376:605–7.
 23. Rudd RA, Seth P, David F, et al. Increases in drug and opioid-
involved overdose deaths - United States, 2010-2015. MMWR Morb 
Mortal Wkly Rep 2016;65:1445–52.
9Gisev N, et al. BMJ Open 2018;8:e025840. doi:10.1136/bmjopen-2018-025840
Open access
 24. Kochanek KD, Murphy SL, Xu J, et al. Deaths: final data for 2014. 
Natl Vital Stat Rep 2016;65:1–122.
 25. Poudel DR, Acharya P, Ghimire S, et al. Burden of hospitalizations 
related to adverse drug events in the USA: a retrospective analysis 
from large inpatient database. Pharmacoepidemiol Drug Saf 
2017;26:635–41.
 26. Case A, Deaton A. Rising morbidity and mortality in midlife among 
white non-Hispanic Americans in the 21st century. Proc Natl Acad 
Sci U S A 2015;112:15078–83.
 27. Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing 
opioids for chronic pain - United States, 2016. JAMA 
2016;65:1–49.
 28. Center for Drug Evaluation and Research (CDER). Guidance for 
industry: abuse-deterrent opioids – evaluation and labeling. Rockville, 
MD: Food and Drug Administration, US Department of Health and 
Human Services, 2013.
 29. Degenhardt L, Larance B, Peacock A, et al. Reducing extramedical 
use and harms of pharmaceutical opioids: the potential role of 
abuse-deterrent formulations. Lancet Psychiatry 2015;2:957–9.
 30. Therapeutic Guidelines. eTG Complete: analgesic. Melbourne: 
Therapeutic Guidelines Ltd, 2018.
 31. Blyth FM, March LM, Brnabic AJ, et al. Chronic pain in Australia: a 
prevalence study. Pain 2001;89:127–34.
 32. Noble M, Treadwell JR, Tregear SJ, et al. Long-term opioid 
management for chronic noncancer pain. Cochrane Database Syst 
Rev 2010:CD006605.
 33. Roxburgh A, Degenhardt L, Burns L, et al. Opioid-related mortality in 
Australia. Drug Alcohol Rev 2014;33:7.
 34. Gisev N, Pearson SA, Blanch B, et al. Initiation of strong 
prescription opioids in Australia: cohort characteristics and factors 
associated with the type of opioid initiated. Br J Clin Pharmacol 
2016;82:1123–33.
 35. Campbell G, Bruno R, Lintzeris N, et al. Defining problematic 
pharmaceutical opioid use among people prescribed opioids for 
chronic noncancer pain: do different measures identify the same 
patients? Pain 2016;157:1489–98.
 36. Campbell G, Nielsen S, Bruno R, et al. The Pain and Opioids IN 
Treatment study: characteristics of a cohort using opioids to manage 
chronic non-cancer pain. Pain 2015;156:231–42.
 37. Clarke H, Soneji N, Ko DT, et al. Rates and risk factors for prolonged 
opioid use after major surgery: population based cohort study. BMJ 
2014;348:g1251.
 38. Cochran BN, Flentje A, Heck NC, et al. Factors predicting 
development of opioid use disorders among individuals who 
receive an initial opioid prescription: mathematical modeling using a 
database of commercially-insured individuals. Drug Alcohol Depend 
2014;138:202–8.
 39. Rogers KD, Kemp A, McLachlan AJ, et al. Adverse selection? A 
multi-dimensional profile of people dispensed opioid analgesics for 
persistent non-cancer pain. PLoS One 2013;8:e80095.
 40. Sullivan MD. Who gets high-dose opioid therapy for chronic non-
cancer pain? Pain 2010;151:567–8.
 41. World Health Organization. The importance of pharmacovigilance: 
safety monitoring of medicinal products. Geneva: WHO, 2002.
 42. Coste J. Diverging approaches of pharmacovigilance and 
pharmacoepidemiology to assessing drug safety: epistemological 
and ethical implications. Pharmacoepidemiol Drug Saf 
2017;26:600–2.
 43. Califf RM, Woodcock J, Ostroff S. A proactive response to 
prescription opioid abuse. N Engl J Med 2016;374:1480–5.
 44. International Association for the Study of Pain. IASP statement on 
opioids, 2018. http://www. iasp- pain. org/ Advocacy/ Content. aspx? 
ItemNumber= 7194
 45. Mellish L, Karanges EA, Litchfield MJ, et al. The Australian 
Pharmaceutical Benefits Scheme data collection: a practical guide 
for researchers. BMC Res Notes 2015;8:634.
 46. World Health Organization Collaborating Centre for Drugs Statistics 
Methodology. ATC/DDD Index 2018, 2017. http://www. whocc. no/ 
atc_ ddd_ index/ (Accessed 3 Aug 2018).
 47. Gisev N, Pearson SA, Karanges EA, et al. To what extent do data from 
pharmaceutical claims under-estimate opioid analgesic utilisation in 
Australia? Pharmacoepidemiol Drug Saf 2018;27:550–5.
 48. Degenhardt L, Blanch B, Gisev N, et al. The POPPY Research 
Programme protocol: investigating opioid utilisation, costs and patterns of 
extramedical use in Australia. BMJ Open 2015;5:e007030.
 49. Blanch B, Degenhardt L, Buckley NA, et al. Prescription opioid 
access patterns and factors associated with increasing number of 
prescribers, pharmacies, and dispensings: an observational study 
using pharmaceutical claims. Pain Med 2018;19:1170–83.
 50. Blanch B, Daniels B, Litchfield M, et al. Looking forward and 
looking back: the balancing act in new drug user designs for 
pharmacoepidemiological research. Pharmacoepidemiol Drug Saf 
2015;24:1117–9.
 51. Spilsbury K, Rosman D, Alan J, et al. Cross border hospital use: 
analysis using data linkage across four Australian states. Med J Aust 
2015;202:582–6.
 52. Nielsen S, Degenhardt L, Hoban B, et al. A synthesis of oral 
morphine equivalents (OME) for opioid utilisation studies. 
Pharmacoepidemiol Drug Saf 2016;25:733–7.
 53. MIMS Australia. MIMS online: drug interactions. MIMS Australia: St 
Leonards, 2014.
 54. Australian Medicines Handbook. Australian medicines handbook. 
Adelaide: Australian Medicines Handbook Pty Ltd, 2014.
 55. In: Baxter K, Preston CL, eds. Stockley’s drug interactions. 10th edn. 
London: edPharmaceutical Press, 2015.
 56. Ringland C, Mant A, McGettigan P, et al. Uncovering the potential 
risk of serotonin toxicity in Australian veterans using pharmaceutical 
claims data. Br J Clin Pharmacol 2008;66:682–8.
 57. Larance B, Degenhardt L, Lintzeris N, et al. Definitions related to the 
use of pharmaceutical opioids: extramedical use, diversion, non-
adherence and aberrant medication-related behaviours. Drug Alcohol 
Rev 2011;30:236–45.
 58. Bachs LC, Bramness JG, Engeland A, et al. Repeated dispensing of 
codeine is associated with high consumption of benzodiazepines. 
Nor Epidemiol 2008;18:185–90.
 59. Logan J, Liu Y, Paulozzi L, et al. Opioid prescribing in emergency 
departments: the prevalence of potentially inappropriate prescribing 
and misuse. Med Care 2013;51:646–53.
 60. White AG, Birnbaum HG, Schiller M, et al. Analytic models to identify 
patients at risk for prescription opioid abuse. Am J Manag Care 
2009;15:897–906.
 61. Bramness JG, Furu K, Engeland A, et al. Carisoprodol use and abuse 
in Norway: a pharmacoepidemiological study. Br J Clin Pharmacol 
2007;64:210–8.
 62. Frauger E, Pauly V, Thirion X, et al. Estimation of clonazepam abuse 
liability: a new method using a reimbursed drug database. Int Clin 
Psychopharmacol 2009;24:318–24.
 63. Frauger E, Pauly V, Natali F, et al. Patterns of methylphenidate 
use and assessment of its abuse and diversion in two French 
administrative areas using a proxy of deviant behaviour determined 
from a reimbursement database: main trends from 2005 to 2008. 
CNS Drugs 2011;25:415–24.
 64. Wilsey BL, Fishman SM, Gilson AM, et al. Profiling multiple provider 
prescribing of opioids, benzodiazepines, stimulants, and anorectics. 
Drug Alcohol Depend 2010;112:99–106.
 65. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality 
from 235 causes of death for 20 age groups in 1990 and 2010: a 
systematic analysis for the Global Burden of Disease Study 2010. 
Lancet 2012;380:2095–128.
 66. Cepeda MS, Fife D, Chow W, et al. Opioid shopping behavior: how 
often, how soon, which drugs, and what payment method. J Clin 
Pharmacol 2013;53:112–7.
 67. Cepeda MS, Fife D, Yuan Y, et al. Distance traveled and frequency of 
interstate opioid dispensing in opioid shoppers and nonshoppers. 
 J Pain 2013;14:1158–61.
 68. Cepeda MS, Fife D, Chow W, et al. Assessing opioid shopping 
behaviour: a large cohort study from a medication dispensing 
database in the US. Drug Saf 2012;35:325–34.
 69. Peirce GL, Smith MJ, Abate MA, et al. Doctor and pharmacy 
shopping for controlled substances. Med Care 2012;50:494–500.
 70. Pradel V, Thirion X, Ronfle E, et al. Assessment of doctor-shopping 
for high dosage buprenorphine maintenance treatment in a French 
region: development of a new method for prescription database. 
Pharmacoepidemiol Drug Saf 2004;13:473–81.
 71. Martyres RF, Clode D, Burns JM. Seeking drugs or seeking help? 
Escalating “doctor shopping” by young heroin users before fatal 
overdose. Med J Aust 2004;180:211–4.
 72. Braker LS, Reese AE, Card RO, et al. Screening for potential 
prescription opioid misuse in a michigan medicaid population. Fam 
Med 2009;41:729–34.
 73. Katz N, Panas L, Kim M, et al. Usefulness of prescription monitoring 
programs for surveillance--analysis of Schedule II opioid prescription 
data in Massachusetts, 1996-2006. Pharmacoepidemiol Drug Saf 
2010;19:115–23.
 74. Rice JB, White AG, Birnbaum HG, et al. A model to identify patients 
at risk for prescription opioid abuse, dependence, and misuse. Pain 
Med 2012;13:1162–73.
 75. Seal KH, Shi Y, Cohen G, et al. Association of mental health 
disorders with prescription opioids and high-risk opioid use in US 
veterans of Iraq and Afghanistan. JAMA 2012;307:940–7.
 76. Larance B, Dobbins T, Peacock A, et al. The effect of a potentially 
tamper-resistant oxycodone formulation on opioid use and harm: 
10 Gisev N, et al. BMJ Open 2018;8:e025840. doi:10.1136/bmjopen-2018-025840
Open access 
main findings of the National Opioid Medications Abuse Deterrence 
(NOMAD) study. Lancet Psychiatry 2018;5:155–66.
 77. Box GE, Jenkins GM, Reinsel GC, et al. Time series analysis: 
forecasting and control. New Jersey: John Wiley & Sons, 2015.
 78. Zhang F, Wagner AK, Ross-Degnan D. Simulation-based power 
calculation for designing interrupted time series analyses of health 
policy interventions. J Clin Epidemiol 2011;64:1252–61.
 79. Benchimol EI, Smeeth L, Guttmann A, et al. The REporting of studies 
Conducted using Observational Routinely-collected health Data 
(RECORD) statement. PLoS Med 2015;12:e1001885.
 80. Australian Bureau of Statistics. 2033.0.55.001 - Census of population 
and housing: Socio-Economic Indexes for Areas (SEIFA), Australia, 
2011, 2013. http://www. abs. gov. au/ AUSSTATS/ abs@. nsf/ DetailsPage/ 
2033. 0. 55. 0012011? OpenDocument (Accessed 3 Aug 2018).
 81. Australian Bureau of Statistics. 1216.0.15.003 - Australian 
Standard Geographical Classification (ASGC) remoteness 
area correspondences, 2006, 2007. http://www. abs. gov. au/ 
AUSSTATS/ abs@. nsf/ Lookup/ 1216. 0. 15. 003Main+ Features12006? 
OpenDocument (Accessed 3 Aug 2018).
 82. World Health Organization. International Statistical Classification of 
Diseases and Related Health Problems 10th Revision (ICD-10), 2016. 
http:// apps. who. int/ classifications/ icd10/ browse/ 2015/ en#/ C80.9 
(Accessed 3 Aug 2018).
 83. World Health Organization. International Classification of Diseases 
for Oncology (ICD-O-3). 2013 http:// codes. iarc. fr/.
 84. Charlson M, Szatrowski TP, Peterson J, et al. Validation of a 
combined comorbidity index. J Clin Epidemiol 1994;47:1245–51.
 85. Sloan KL, Sales AE, Liu CF, et al. Construction and characteristics of 
the RxRisk-V: a VA-adapted pharmacy-based case-mix instrument. 
Med Care 2003;41:761–74.
 86. Pratt NL, Kerr M, Barratt JD, et al. The validity of the Rx-Risk 
Comorbidity Index using medicines mapped to the Anatomical 
Therapeutic Chemical (ATC) Classification System. BMJ Open 
2018;8:e021122.
